Prolonged activity of factor IX as a monomeric Fc fusion protein

Blood

Volumn 115, Issue 10, 2010, Pages 2057-2064

  Peters, Robert T ^a   Low, Susan C ^a   Kamphaus, George D ^a   Dumont, Jennifer A ^a   Amari, John V ^a   Lu, Qi ^a   Zarbis Papastoitsis, Greg ^a   Reidy, Thomas J ^a   Merricks, Elizabeth P ^b   Nichols, Timothy C ^b   Bitonti, Alan J ^a  

^a BIOGEN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; FC RECEPTOR; HYBRID PROTEIN; MONOMER; RECOMBINANT FACTOR IX; RECOMBINANT FACTOR IX FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING TIME; CELL STRAIN HEK293; CIRCULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EMBRYO; FEMALE; HALF LIFE TIME; HEMOPHILIA B; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

EID: 77950391547     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-08-239665     Document Type: Article

References (36)

1. Peyvandi F, Jayandharan G, Chandy M, et al. Genetic diagnosis of haemophilia and other inherited bleeding disorders. Haemophilia. 2006;(12 suppl 3):82-89.
2. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773-1779. (Pubitemid 32497033)
3. Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother. 2005;6(9):1517-1524.
4. Fischer K, Van Den Berg M. Prophylaxis for severe haemophilia: clinical and economical issues. Haemophilia. 2003;9(4):376-381. (Pubitemid 36874384)
5. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
6. Ljung RC. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost. 1999;82(2):525-530.
7. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78(1):261-265.
8. National Hemophilia Foundation no. 179. MASAC recommendation concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). November 2007. http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx? menuid57&contentid1007. Accessed November 4, 2007.
9. Roopenian DC, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715-725. (Pubitemid 47327396)
10. Ghetie V, Ward ES. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Ann Rev Immunol. 2000;18:739-766. (Pubitemid 30365396)
11. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual. Plainview, NY: Cold Spring Harbor Laboratory Press; 1989.
12. Lusson J, Vieau D, Hamelin J, et al. cDNA structure of the mouse and rat subtilisin/kexin-like PC5: a candidate proprotein convertase expressed in endocrine and nonendocrine cells. Proc Natl Acad Sci U S A. 1993;90(14):6691- 6695. (Pubitemid 23207279)
13. Yan SB. Review of conformation-specific affinity purification methods for plasma vitamin K-dependent proteins. J Mol Recognit. 1996;9(3):211-218.
14. Gillis S, Furie BC, Furie B, et al. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function. Protein Sci. 1997;6(1):185-196. (Pubitemid 27045258)
15. Pedicord DL, Seiffert D, Blat Y. Substrate-dependent modulation of the mechanism of factor XIa inhibition. Biochemistry. 2004;43(37):11883-11888. (Pubitemid 39277635)
16. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966. (Pubitemid 27484049)
17. Roopenian DC, Christianson GJ, Sproule TJ, et al. The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs. J Immunol. 2003;170(7):3528-3533.
18. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A. 1989;86(24):10095-10099.
19. Kay MA, Rothenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262(5130):117-119.
20. Margaritis P, Roy E, Aljamali MN, et al. Successful and safe treatment of canine hemophilia by continuous expression of canine FVIIa: a model for FVIII/FIX gene-based bypassing agents [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11): Abstract 4.
21. Bond M, Jankowski M, Patel H, et al. Biochemical characterization of recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):11-17.
22. Brinkhous KM, Sigman JL, Read MS, et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood. 1996;88(7):2603-2610.
23. McCarthy K, Stewart P, Sigman J, et al. Pharmacokinetics of recombinant factor IX after intravenous and subcutaneous administration in dogs and cynomolgus monkeys. Thromb Haemost. 2002;87(5):824-830. (Pubitemid 34516609)
24. Keith JC Jr, Ferranti TJ, Misra B, et al. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog. Thromb Haemost. 1995;73(1):101-105.
25. Burmeister WP, Huber AH, Bjorkman PJ. Crystal structure of the complex of rat neonatal Fc receptor with Fc. Nature. 1994;372(6504):379-383. (Pubitemid 24363442)
26. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta 2-microglobulin-containing neonatal intestinal transport receptor. Proc Natl Acad Sci U S A. 1996;93(11):5512-5516. (Pubitemid 26159481)
27. Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack beta 2-microglobulin: possible protective role of FcRn. Immunology. 1996;89(4):573-578. (Pubitemid 26419660)
28. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol. 1996;26(3):690-696. (Pubitemid 26091401)
29. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001;40(11):815-832. (Pubitemid 33095998)
30. Thompson A. Recombinant factor IX for the treatment of hemophilia B. Introduction. Semin Hematol. 1998;35(2 suppl 2):1-3. (Pubitemid 28177993)
31. Furie B, Furie BC. Molecular basis of hemophilia. Semin Hematol. 1990;27(3):270-285.
32. Harrison S, Adamson S, Bonam D, et al. The manufacturing process for recombinant factor IX. Semin Hematol. 1998;35(2 suppl 2):4-10.
33. Berkner K. Expression of recombinant vitamin K-dependent proteins in mammalian cells: factors IX and VII. Methods Enzymol. 1993;222:450-477.
34. Ashkenazi A, Capon DJ, Ward RH. Immunoadhesins. Int Rev Immunol. 1993;10(2-3):219-227.
35. Bitonti AJ, Dumont JA, Low SC, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A. 2004;101(26):9763-9768.
36. Dumont JA, Low SC, Peters RT, Bitonti AJ. Monomeric Fc fusion molecules. In: An Z, ed. Therapeutic Monoclonal Antibodies: from Bench to Clinic. Hoboken, NJ: John Wiley and Sons; 2009:P775-P788.